GLPG2737-CL-105 Assessment of multiple oral doses of GLPG2451/GLPG2222
Details
- Therapeutic approach
- Restore CFTR Function
- Trial status
- Closed with results Participating Centres
- Trials Tracker ID
- TT001846
- Last updated
- 20/12/2017
Full title
Assessment of safety, tolerability, pharmacokinetics and pharmacodynamics of multiple oral doses of the combination of GLPG2451 and GLPG2222, with or without GLPG2737, in adult subjects with cystic fibrosis
Study detailsThis is a Phase Ib, multi-center, open-label, nonrandomized multiple cohorts study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of a combination treatment of GLPG2451 and GLPG2222, with and without GLPG2737, in adult subjects with Cystic Fibrosis.
- Phase
- Phase 1
- Recruitment target
- 24
- CF sponsor
- Galapagos
- CF sponsor type
- Commercial
Who can take part?
- Age range
- 18+
- Including people
Homozygous or Heterozygous (with non-responsive mutation on 2nd allele) for F508del mutation
Sweat chloride concentration ≥60 mmol/L at screening.
A body weight of ≥40 kg at screening.- Excluding people
Medical history of cataract (or lens opacity) and/or glaucoma.